Abacus Bioscience is developing a new class of immunotherapy that unleashes the power of a novel CD180 platform technology. Our Antigen-Specific Immune Accelerants (ASIA) are POTENT, SPECIFIC and DURABLE, with broad applications across infectious disease and oncology.
Location: United States, Washington, Seattle
Employees: 1-10
Total raised: $4.4M
Founded date: 2017
Founders name: Edward A Clark; Craig W. Philips
Founders Related Locations: United States, Washington, Seattle
Investors 2
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
| - | Sahsen Ven... | sahsen.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.01.2023 | Seed | $4.4M | - |
Persons 4
| Date | First Name | Last Name | Title | Location | |||
| - | Craig W. | Philips | Board Memb... | linkedin.c... | - | C******s@a... | - |
| - | Alan | Wahl | Chief Exec... | linkedin.c... | - | a***l@abac... | - |
| - | Che-Leung | Law | Chief Scie... | linkedin.c... | - | c**w@abacu... | - |
| - | Edward | A Clark | Founder an... | linkedin.c... | - | - | - |
Mentions in press and media 1
| Date | Title | Description | Source |
| - | Abacus Bioscience | “First-in-Class Active Immunotherapies that overcome immune tolerance to treat cancer and chronic in... | fastfounde... |